DAFTAR PUSTAKA

1. GCO (2020). Cancer Fact Sheets. Global Cancer Observatory. https://gco.iarc.fr/today/fact-sheets-cancers - Diakses Oktober 2021.

2. Hwang SY, Park S, Kwon Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Elsevier Inc.2019;199:30–57.

3. Bergin ART, Loi S. Triple-negative breast cancer: Recent treatment advances.F1000 Research. 2019;8:3-4.

4. Purwanto I, Dwiprahasto I, Aryandono T, Mubarika S. Treatment options for Indonesian triple negative breast cancer patients: a literature review of current state and potentials for future improvement. JMedSci. 2020;52:81–83.

5. Purwanto I, Heriyanto DS, Ghozali A, Widodo I, Dwiprahasto I, Aryandono T, et al. Overexpression of programmed death-ligand 1 receptor mRNA as an independent negative prognostic factor for triple negative breast cancer. World J Oncol. 2020;11:216–22.

6. Al Farisyi M, Khambri D. Analisis survival pasien kanker payudara usia muda di RSUP Dr. M. Djamil Padang tahun 2008-2017. JKA. 2018;7:25.

7. Jitariu AA, Cîmpean AM, Ribatti D, Raica M. Triple negative breast cancer: the kiss of death the emerging concept of triple negative breast cancer.2017;8.

8. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress.Breast Cancer Research.BioMed Central.2020;22.

9. Elimimian EB, Samuel TA, Liang H, Elson L, Bilani N, Nahleh ZA. Clinical and demographic factors, treatment patterns, and overall survival associated with rare triple-negative breast carcinomas in the US. JAMA Netw Open. 2021;4:e214123.

10. Gao G, Wang Z, Qu X, Zhang Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20:179.

11. Rinaldi RM, Sapra A, Bellin LS. Breast lymphatics. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2022.

12. Wu SG, Wang J, Lian CL, Lei J, Hua L, Lin Q, et al. Evaluation of the 8th edition of the American joint committee on cancer's pathological staging system in prognosis assessment and treatment decision making for stage T1-2N1 breast cancer after mastectomy. Breast. 2020;51:2–10.

13. Wang Y, Acs B, Robertson S, Liu B, Solorzano L, Wählby C, et al. Improved breast cancer histological grading using deep learning. Annals of Oncology. 2022;33:89–98.

14. Elobaid Y, Aamir M, Grivna M, Suliman A, Attoub S, Mousa H, et al. Breast cancer survival and its prognostic factors in the United Arab Emirates: A retrospective study. PLoS One. 2021;16.

15. Makower D, Lin J, Xue X, Sparano JA. Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. NPJ Breast Cancer. 2021;7:20.

16. Kariri YA, Aleskandarany MA, Joseph C, Kurozumi S, Mohammed OJ, Toss MS, et al. Molecular complexity of lymphovascular invasion: The Role of Cell Migration in Breast Cancer as a Prototype. Pathobiology. 2020;87:218–31.

17. Ozer SP, Barut SG, Ozer B, Catal O, Sit M. The relationship between tumor budding and survival in colorectal carcinomas. Rev Assoc Med Bras. 2019 ;65:1442–7.

18. Mittal A, Mani NS. Molecular classification of breast cancer. Indian J Pathol Oncol. 2021;8:241–7.

19. Agarwal G, Nanda G, Lal P, Mishra A, Agarwal A, Agrawal V, et al. Outcomes of triple-negative breast cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages? World J Surg. 2016 ;40:1362–72.

20. Ahn KJ, Park J, Choi Y. Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery. Radiat Oncol J. 2017 ;35(4):332–9.

21. Resti Putri Firdaus V, Asri A, Khambri D, Arif Harahap W. Hubungan grading histopatologi dan infiltrasi limfovaskular dengan subtipe molekuler pada kanker payudara invasif di bagian bedah RSUP. Dr. M. Djamil Padang. JKA. 2016;5.

22. Zhong YM, Tong F, Shen J. Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis. BMC Cancer. 2022;22:102.

23. PDQ Adult Treatment Editorial Board. Breast cancer treatment (adult) (PDQ®): Patient Version. National Cancer Institute (US). 2022.

24. Won KA, Spruck C. Triple-negative breast cancer therapy: Current and Future Perspectives. Int J Oncol. 2020;57:1245–61.

25. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic

markers, and current treatment strategies—An updated review. Cancers (Basel). 2021;13:4287.

26. Monneret C. What is an endocrine disruptor? C R Biol. 2017;340:403–5.

27. Zubair M, Wang S, Ali N. Advanced approaches to breast cancer classification and diagnosis. Front Pharmacol. 2021;11.

28. World Health Organization, International Agency for Research on Cancer. Breast tumours.WHO. 2019;2:356.

29. Santika Hyperastuty A, Setijo AR. Artificial neural network dalam menentukan grading histopatologi kanker payudara .Jurnal Biosains Pascasarjana. 2017;19.

30. Syarti A, Pasaribu U, Fauziah D, Mardiyana L, Wulanhandarini T. Characteristics and histopathological grading of malignant spiculated mass in regards to histopathological grading of breast cancer based on the nottingham grading system. Biomolecular and Health Science Journal. 2020 ;3:33.

31. WHO Classification of Tumours Editorial Board. Breast tumours.World Health Organization. 2019;2:86–87.

32. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Research. 2010;12:207.

33. Jayanthi VSPKSA, Das AB, Saxena U. Grade-specific diagnostic and prognostic biomarkers in breast cancer. Genomics. 2020;112(1):388–96.

34. Ryu YJ, Kang SJ, Cho JS, Yoon JH, Park MH. Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy. Medicine. 2018 ;97(30):11647.

35. Usha L, Dehghan-Paz I, van Golen KL, Il'yasova D. Tipifarnib and farnesyltransferase inhibitors in the treatment of inflammatory breast cancer: is the story over? A review. Orphan Drugs: Research and Reviews. 2013;11.

36. Sobočan M, Turk M, Čater P, Sikošek NČ, Crnobrnja B, Takač I, et al. Clinical features and their effect on outcomes of patients with triple negative breast cancer with or without lymph node involvement. Journal of International Medical Research. 2020;48(3).

37. Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, et al. A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. Br J Cancer. 2019;120:1129–36.

38. Kariri YA, Aleskandarany MA, Joseph C, Kurozumi S, Mohammed OJ, Toss MS, et al. Molecular complexity of lymphovascular invasion: the role of cell migration in breast cancer as a prototype. Pathobiology. 2020;87:218–31.

39. Khairana I, Heriady Y. Hubungan grading histopatologi dengan invasi limfovaskular pada penderita kanker payudara di RSUD Al-Ihsan Bandung.Bandung Conference Series : Medical Science. 2022;2.

40. Sejati F, Rizki K, Yohana R. Hubungan derajat histopatologi dan invasi limfovaskular terhadap metastasis kelenjar getah bening aksila pada kanker payudara dini. Medika Kartika Jurnal Kedokteran dan Kesehatan. 2019 ;3:37–49.

41. Bellizzi AM. An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin. Adv Anat Pathol. 2020;27:114–63.

42. Rizk EM, Gartrell RD, Barker LW, Esancy CL, Finkel GG, Bordbar DD, et al. Prognostic and predictive immunohistochemistry-based biomarkers in cancer and immunotherapy. Hematol Oncol Clin North Am. 2019;33:291–9.

43. Magaki S, Hojat SA, Wei B, So A, Yong WH. An introduction to the performance of immunohistochemistry. Methods Mol Biol. 2019;1897:289–98.

44. de Cicco P, Catani MV, Gasperi V, Sibilano M, Quaglietta M, Savini I. Nutrition and breast cancer: A literature review on prevention, treatment and recurrence. Nutrients. 20193;11:1514.

45. Nascimento RG do, Otoni KM. Histological and molecular classification of breast cancer: what do we know?. Mastology. 2020;30.

46. Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res. 2019;8:1342.

47. Marotti JD, de Abreu FB, Wells WA, Tsongalis GJ. Triple-Negative Breast Cancer. Am J Pathol. 2017;187:2133–8.

48. Garmpis N, Damaskos C, Garmpi A, Nikolettos K, Dimitroulis D, Diamantis E, et al. Molecular classification and future therapeutic challenges of triple-negative breast cancer. In Vivo (Brooklyn). 2020;34:1715–27.

49. Won KA, Spruck C. Triple-negative breast cancer therapy: Current and future perspectives (Review). Int J Oncol. 2020;57:1245–61.

50. Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Current Oncology. Multimed Inc. 2018;25:S142–50.

51. Nwagu GC, Bhattarai S, Swahn M, Ahmed S, Aneja R. Prevalence and mortality of triple-negative breast cancer in West Africa: Biologic and cociocultural factors. JCO Glob Oncol. 2021;7:1129–40.

52. Widodo I, Dwianingsih EK, Aryandono T, Soeripto S. Clinicopathological characteristic and prognostic significance of Indonesian triple negative breast cancer. The Indonesian Biomedical Journal. 2019 ;11(3):286–92.

53. Helmi AF, Daan Khambri, Rony Rustam. The relationship of breast cancer subtypes with the event of metastasis in Dr. M. Djamil Hospital Padang. Bioscientia Medicina : Journal of Biomedicine and Translational Research. 2021;5(4):1199–205.

54. Radosevic-Robin N, Selenica P, Zhu Y, Won HH, Berger MF, Ferrando L, et al. Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. NPJ Breast Cancer. 2021;7(1):124.

55. Archer M, Kyprianou N. Homeless cells escape death and deliver lethal cancer. Endocrinology. 2021;162(4).

56. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment. Cancer Discov. 2019;9(2):176–98.

57. Dees S, Ganesan R, Singh S, Grewal IS. Emerging CAR-T cell therapy for the treatment of triple-negative breast cancer. Mol Cancer Ther. 2020 ;19(12):2409–21.

58. Zubair M, Wang S, Ali N. Advanced approaches to breast cancer classification and diagnosis. Front Pharmacol. 2021;11.

59. Khambri D, Rustam R, Rachman A. Manajemen Terapi Kanker Payudara Triple Negative. In: Manajemen Terkini Kanker Payudara. 1st ed. 2017. 208–16.

60. National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer. 2022. https://seer.cancer.gov/statfacts/html/breast.html- Diakses Mei 2021.

61. Koleckova M, Ehrmann J, Bouchal J, Janikova M, Brisudova A, Srovnal J, et al. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer. Sci Rep. 2021;11:5145.

62. Na YM, Ryu YJ, Cho JS, Park MH, Yoon JH. Lymphovascular invasion as a predictive factor for recurrence in triple-negative breast cancer. Indian Journal of Surgery. 2021;83:475–83.

63. He KW, Sun JJ, Liu ZB, Zhuo PY, Ma QH, Liu ZY, et al. Prognostic significance of lymphatic vessel invasion diagnosed by D2-40 in Chinese invasive breast cancers. Medicine (United States). 2017;96.

64. Hermansyah D, Rahayu Y, Azrah A, Pricilia G, Sufida S, Rifsal D, et al. Triple-negative breast cancer clinicopathology: A single-center experience. Indonesian Journal of Cancer. 2021;15:125.

66. Dahlan S. Statistik untuk Kedokteran dan Kesehatan Deskriptif, Bivariat, dan Multivariat.Jakarta Timur: PT. Epidemiologi Indonesia. 2014;1165–178.

67. Sanges F, Floris M, Cossu-Rocca P, Muroni MR, Pira G, Urru SAM, et al. Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis. BMC Cancer. 2020;20:491.

68. Balkenhol MCA, Vreuls W, Wauters CAP, Mol SJJ, van der Laak JAWM, Bult P. Histological subtypes in triple negative breast cancer are associated with specific information on survival. Ann Diagn Pathol. 2020;46:151490.

69. Anna Bethania K, Rustamadji P. Hubungan subtipe molekular pada karsinoma payudara invasif dengan grade, invasi limfovaskular dan metastasis KGB di Departemen Patologi Anatomik FKUI/RSCM Tahun 2019. Maj Patol Indones. 2022;31:392–9.

70. Zhao S, Zuo WJ, Shao ZM, Jiang YZ. Molecular subtypes and precision treatment of triple-negative breast cancer. Ann Transl Med. 2020;8:499–499.

71. Rayson D, Payne JI, Michael JCR, Tsuruda KM, Abdolell M, Barnes PJ. Impact of detection method and age on survival outcomes in triple-negative breast cancer: A population-based cohort analysis. Clin Breast Cancer. 2018 ;18(5):955–60.

72. Aapro M, Wildiers H. Triple-negative breast cancer in the older population. Annals of Oncology. 2012 ;23:52–5.

73. Zhai Z, Zheng Y, Yao J, Liu Y, Ruan J, Deng Y, et al. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer. JAMA Netw Open. 2020;3:e2021881.

74. Prasad S, Efird JT, James SE, Walker PR, Zagar TM, Biswas T. Failure patterns and survival outcomes in triple negative breast cancer (TNBC): a 15 year comparison of 448 non-Hispanic black and white women. Springerplus. 2016;5:756.

75. Hikmanti A, Hanum F, Adriani N, Harapan S, Purwokerto B. Analisis Faktor-Faktor yang Mempengaruhi Keterlambatan Pengobatan pada Wanita Penderita Kanker Payudara.2014:2-6

76. Subiyanto D, Kadi TA, Ismaiyah I, Abdurrahman N, Utomo YP, Alifiansyah AR, et al. Subtipe molekuler kanker payudara di RSUD Madiun dan hubungannya dengan grading histopatologi. Media Penelitian dan Pengembangan Kesehatan. 2021;31:193–202.

77. Widodo I, Dwianingsih EK, Aryandono T, Soeripto. Clinicopathological characteristic and prognostic significance of indonesian triple negative breast cancer. Indonesian Biomedical Journal. 2019;11:286–92.

78. Aapro M, Wildiers H. Triple-negative breast cancer in the older population. Annals of Oncology. 2012;23:52–5.

79. Fan L, Goss PE, Strasser-Weippl K. Current status and future projections of breast cancer in Asia. Breast Care. 2015;10:372–8.

80. Kartini K, Lubis NL, Moriza T. Analisis Faktor Yang Mempengaruhi Keterlambatan Pengobatan Pada Wanita Penderita Kanker Payudara Di Rumah Sakit Umum Daerah Simeulue Tahun 2018. Jurnal Info Kesehatan. 2019;17:16–34.

81. Aulia U, Wibowo A, Notobroto HB. The affecting factors to grade of breast cancer in Dr. Soetomo Hospital of Surabaya. Health Notions. 2018;2(6).

82. Houvenaeghel G, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, et al. Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. ESMO Open. 2021;6:100316.

83. Verma R, Lal Jakhar S, Sharma N, Kumar HS, Beniwal S. Epidemiological profile and clinicopathological correlates of triple negative breast cancer patients at regional cancer centre. Asian Pacific Journal of Cancer Care. 2021 ;6:457–60.

84. Jitariu AA, Cîmpean AM, Ribatti D, Raica M. Triple negative breast cancer: the kiss of death. Oncotarget. 2017;8:46652–62.

85. Deschairul K, Puspasari D, Dewi M, Astuti K, Karlowee V, Listiana DE. Hubungan ekspresi E-Cadherin dengan status metastasis kelenjar getah bening pada triple negative breast cancer di rumah sakit umum pusat Dr. Kariadi. Jurnal Ilmu Kedokteran dan Kesehatan. 2022;9.

86. William M M, Sonya B. Triple-negative breast cancer: What crucial information can imaging add to the diagnosis, treatment and prognosis? Int J Womens Health Wellness. 2019;5(1).